Table 2.
Variable notations, definitions, and dimensions.
| Variable | Definition | Dimensions i=23 age groups l=3 sexual activity groups c=2 gender groups |
|---|---|---|
| X | Susceptible, female persons | l, i, c+1 |
| V1 | Vaccinated with 1 dose | l, i, c+1 |
| V2 | Vaccinated with 2 doses | l, i, c+1 |
| VS | Vaccinated with waned immunity | l, i, c+1 |
| Y | Infected persons | l, i, c+1 |
| UF | Persistently infected, only female | l, i, c |
| ZS | Recovered without sero-conversion | l, i, c+1 |
| Z | Recovered with sero-conversion | l, i, c+1 |
| WS | Infected vaccinated with waned immunity | l, i, c+1 |
| W1 | Infected vaccinated with 1 dose | l, i, c+1 |
| W2 | Infected vaccinated with 2 doses | l, i, c+1 |
| PSF | Persistently infected vaccinated, only female | l, i, c |
| P1F | Persistently infected vaccinated with 1 dose, only female | l, i, c |
| P2F | Persistently infected vaccinated with 2 doses, only female | l, i, c |
| QS | Recovered vaccinated without sero-convertion | l, i, c+1 |
| Q | Recovered vaccinated with sero-convertion | l, i, c+1 |
| Hx | Population of females with hysterectomy | l, i, c |
| Hy | Population of females with hysterectomy that are infected | l, i, c |
| Hz | Population of females with hysterectomy that were infected, recovered, seroconverted | l, i, c |
| Hzs | Population of females with hysterectomy that were infected, recovered, not seroconverted | l, i, c |
| Hv1 | Vaccinated with 1 dose, persons with hysterectomy | l, i, c |
| Hv2 | Vaccinated with 2 doses, persons with hysterectomy | l, i, c |
| Hvs | Vaccinated with waned immunity, persons with hysterectomy | l, i, c |
| Hw | Infected vaccinated, persons with hysterectomy | l, i, c |
| Hqs | Recovered vaccinated without sero-convertion, persons with hysterectomy | l, i, c |
| Hq | Recovered vaccinated with sero-convertion, persons with hysterectomy | l, i, c |
| N | Total number of persons | l, i, c |
| CIN2 | Undetected cervical intraepithelial neoplasia 2 | l, i, c |
| CIN3 | Undetected cervical intraepithelial neoplasia 3 | l, i, c |
| CIS | Undetected carcinoma in situ 1 | l, i, c |
| DCIN2 | Detected cervical intraepithelial neoplasia 2 | l, i, c |
| DCIN3 | Detected cervical intraepithelial neoplasia 3 | l, i, c |
| DCIS | Detected carcinoma in situ 1 | l, i, c |
| TCIN2 | Treated cervical intraepithelial neoplasia 2 | l, i, c |
| TCIN3 | Treated cervical intraepithelial neoplasia 3 | l, i, c |
| TCIS | Treated carcinoma in situ | l, i, c |
| ICIN2 | Infectious after treatment cervical intraepithelial neoplasia 2 | l, i, c |
| ICIN3 | Infectious after treatment cervical intraepithelial neoplasia 3 | l, i, c |
| ICIS | Infectious after treatment carcinoma in situ 1 | l, i, c |
| CCl | Undetected local cervical cancer | l, i, c |
| CCr | Undetected regional cervical cancer | l, i, c |
| CCd | Undetected distant cervical cancer | l, i, c |
| DCCl | Detected local cervical cancer | l, i |
| DCCr | Detected regional cervical cancer | l, i |
| DCCd | Detected distant cervical cancer | l, i |
| SCC | Cervical cancer survivals | l, i |